A laboratory study found that a modified enterocyte preparation retained several metabolic activities. Its midazolam assay was a probe of intestinal metabolism, not a clinical sedation experiment.
The investigators compared conventional cryopreserved human enterocytes with a permeabilized, cofactor-supplemented preparation. Midazolam hydroxylation was used to assess CYP3A4 activity alongside probes for other enzymes.
Both preparations were active, and the modified system showed higher specific activity for several tested pathways. The practical advantages concerned storage and laboratory handling.
A permeabilized cell system with supplied cofactors does not reproduce every barrier, blood-flow condition, transporter, or exposure present in a living intestine. Increased assay activity does not directly establish lower oral bioavailability or faster awakening in patients.
The study did not measure actual blood concentrations after a clinical midazolam dose. For pharmacokinetic interpretation, distinguish intestinal metabolism, hepatic metabolism, systemic exposure, and functional effect. This paper supports an experimental tool for studying one part of that sequence, while requiring additional assumptions to predict an individual patient’s response.
Original analysis of the supplied journal article, identified as PMC6350199.